NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球反肥胖處方藥市場規模調查:按藥物類別,年齡組,分銷渠道-2025年的全球預測-COVID-19的累積影響

Anti-obesity Prescription Drugs Market Research Report by Drug Class, by Age Group, by Distribution Channel, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 990533
出版日期 內容資訊 英文 192 Pages
商品交期: 最快1-2個工作天內
價格
全球反肥胖處方藥市場規模調查:按藥物類別,年齡組,分銷渠道-2025年的全球預測-COVID-19的累積影響 Anti-obesity Prescription Drugs Market Research Report by Drug Class, by Age Group, by Distribution Channel, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 192 Pages
簡介

全球抗肥胖處方藥市場預計將從2020年的4,965,820,000美元增長到2025年底的6,949,080,000美元。

市場細分和覆蓋率

這項研究對抗肥胖處方藥進行了分類,預測了收入,並分析了以下每個子市場的趨勢。

根據藥物類別,對安非他酮和納曲酮,利拉魯□,洛卡西林,奧利司他,芬特明和托□酯的抗肥胖處方藥市場進行了調查。

按年齡組,對成人和兒童的抗肥胖處方藥市場進行了調查。

通過分銷渠道,對醫院藥房,在線藥房和零售藥房進行了調查。

按地區,在美國,亞太地區,歐洲和中東/非洲對抗肥胖處方藥市場進行了調查。

COVID-19的累積影響

COVID-19預計將在預測期內對行業增長產生長期影響,因為這是無與倫比的全球公共衛生突發事件,幾乎影響了每個行業。我們正在進行的研究擴大了研究框架,以確保它包括潛在的COVID-19問題和潛在的未來路徑。該調查提供了對COVID-19的見解,並考慮了消費者行為和需求,購買模式,供應鏈改路,當前市場勢力動態以及政府的主要干預措施的變化。更新後的調查提供了見解,分析,估計和預測,其中考慮了COVID-19對市場的影響。

報告提供了有關以下準則的見解:

1.市場滲透率:主要參與者提供的全面市場信息

2.市場開發:有利可圖的新興市場的詳細信息和市場分析

3.市場多元化:有關新產品發佈,欠發達地區,最新發展和投資的更多信息

4.競爭評估和情報:全面評估主要公司的市場份額,戰略,產品和製造能力

5.產品開發和創新:對未來技術,研發活動和新產品開發的智能見解

報告回答以下問題:

1.全球市場的規模和預測是什麼?

2.在預測期內,構成市場的COVID-19有哪些障礙和影響?

3.在預測期內,您將投資哪些產品,細分市場,應用或領域?

4.市場機會的競爭性戰略窗口是什麼?

5.市場的技術趨勢和監管框架是什麼?

6.哪些模式和戰略舉措被認為適合進入市場?

該報告調查了抗肥胖處方藥市場,分析了市場概況,市場增長和障礙以及按藥物類別,年齡組,分銷渠道和地區劃分的市場規模趨勢和預測。COVID-19累積影響,競爭狀況,領先的公司簡介,市場機會等。

目錄

第1章簡介

  • 調查目的
  • 市場細分和覆蓋範圍
  • 調查對像年度
  • 貨幣和價格
  • 語言
  • 限制
  • 利益相關者

第2章調查方法

  • 調查過程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:測量設備
    • 集合:數據源
    • 分析:數據解釋
    • 公式:數據驗證
    • 已發佈:調查報告
    • 重複:報告更新
  • 進行調查
    • 開始:調查過程
    • 計劃:創建調查計劃
    • 執行:進行調查
    • 驗證:發現和分析
    • 出版物:調查報告
  • 調查結果

第3章執行摘要

  • 簡介
  • 市場前景
  • 毒品類別的展望
  • 按年齡段劃分的展望
  • 按分銷渠道劃分的Outlook
  • 區域展望
  • 競爭對手的展望

第4章市場概述

  • 簡介
  • COVID-19的累積效果

第5章市場洞察

  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會
    • 挑戰
  • 搬運工五力分析
    • 新進入者的威脅
    • 替代威脅
    • 客戶的議價能力
    • 供應商的談判能力
    • 行業競爭

第6章按藥物類別劃分的全球反肥胖處方藥市場

  • 簡介
  • 安非他酮和納曲酮
  • 利拉魯□
  • Locaseline
  • 奧利斯塔特
  • 芬特明和托□酯

第7章按年齡段劃分的全球抗肥胖處方藥市場

  • 簡介
  • 成人
  • 兒科

第8章,按分銷渠道劃分的全球抗肥胖處方藥市場

  • 簡介
  • 醫院藥房
  • 在線藥房
  • 零售藥房

第9章美洲減肥藥市場

  • 簡介
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太反肥胖處方藥市場

  • 簡介
  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第11章歐洲,中東/非洲反肥胖處方藥市場

  • 簡介
  • 法國
  • 德國
  • 意大利
  • 荷蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合酋長國
  • 英國

第12章競爭情況

  • FPNV定位矩陣
    • 象限
    • 經營策略
    • 產品滿意度
  • 市場排名分析
  • 市場份額分析
  • 競爭性SWOT分析
  • 競爭情景
    • 併購
    • 協議,合作和夥伴關係
    • 推出和增強新產品
    • 投融資
    • 獎項,獎項,擴展

第13章企業可用性概況

  • 7TM Pharma A/S
  • Akrimax Pharmaceuticals Inc
  • Alizyme PLC
  • Arena Pharmaceuticals, Inc
  • Arrowhead Pharmaceuticals
  • Bayer AG
  • Bristol-Myers Squibb Co
  • C.H. Boehringer Sohn AG & Ko. KG
  • Cadila Healthcare Limited
  • Currax Pharmaceuticals LLC
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co.
  • Norgine BV
  • Novo Nordisk A/s
  • Orexigen Therapeutics, Inc
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc,
  • Rhythm Pharmaceuticals, Inc.
  • Shionogi USA Inc
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc
  • VIVUS, Inc
  • Zafgen Inc

第14章附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-4358BACA7FE8

The Global Anti-obesity Prescription Drugs Market size was estimated at USD 4,965.81 Million in 2020 and expected to reach USD 5,342.71 Million in 2021, at a Compound Annual Growth Rate (CAGR) 7.92% to reach USD 7,848.73 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Anti-obesity Prescription Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug Class, the Anti-obesity Prescription Drugs Market was studied across Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate.

Based on Age Group, the Anti-obesity Prescription Drugs Market was studied across Adult and Pediatric.

Based on Distribution Channel, the Anti-obesity Prescription Drugs Market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Based on Geography, the Anti-obesity Prescription Drugs Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-obesity Prescription Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-obesity Prescription Drugs Market, including 7TM Pharma A/S, Akrimax Pharmaceuticals Inc, Alizyme PLC, Arena Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Co, C.H. Boehringer Sohn AG & Ko. KG, Cadila Healthcare Limited, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Norgine BV, Novo Nordisk A/s, Orexigen Therapeutics, Inc, Orexigen Therapeutics, Inc., Pfizer Inc,, Rhythm Pharmaceuticals, Inc., Shionogi USA Inc, Takeda Pharmaceutical Company Limited, Vivus Inc, VIVUS, Inc, and Zafgen Inc.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Anti-obesity Prescription Drugs Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-obesity Prescription Drugs Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-obesity Prescription Drugs Market?
  • 4. What is the competitive strategic window for opportunities in the Global Anti-obesity Prescription Drugs Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Anti-obesity Prescription Drugs Market?
  • 6. What is the market share of the leading vendors in the Global Anti-obesity Prescription Drugs Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Anti-obesity Prescription Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Class Outlook
  • 3.4. Age Group Outlook
  • 3.5. Distribution Channel Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of obesity and related chronic diseases
      • 5.1.1.2. Growing unhealthy and sedentary lifestyle
      • 5.1.1.3. Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
    • 5.1.2. Restraints
      • 5.1.2.1. Side effect related to anti-obesity drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel anti-obesity drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatment options
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Anti-obesity Prescription Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bupropion and Naltrexone
  • 6.3. Liraglutide
  • 6.4. Lorcaserin
  • 6.5. Orlistat
  • 6.6. Phentermine and Topiramate

7. Anti-obesity Prescription Drugs Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adult
  • 7.3. Pediatric

8. Anti-obesity Prescription Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas Anti-obesity Prescription Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Anti-obesity Prescription Drugs Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. 7TM Pharma A/S
  • 13.2. Akrimax Pharmaceuticals Inc
  • 13.3. Alizyme PLC
  • 13.4. Arena Pharmaceuticals, Inc
  • 13.5. Arrowhead Pharmaceuticals
  • 13.6. Bayer AG
  • 13.7. Bristol-Myers Squibb Co
  • 13.8. C.H. Boehringer Sohn AG & Ko. KG
  • 13.9. Cadila Healthcare Limited
  • 13.10. Currax Pharmaceuticals LLC
  • 13.11. Eisai Co., Ltd
  • 13.12. F. Hoffmann-La Roche AG
  • 13.13. GlaxoSmithKline PLC
  • 13.14. Merck & Co.
  • 13.15. Norgine BV
  • 13.16. Novo Nordisk A/s
  • 13.17. Orexigen Therapeutics, Inc
  • 13.18. Orexigen Therapeutics, Inc.
  • 13.19. Pfizer Inc,
  • 13.20. Rhythm Pharmaceuticals, Inc.
  • 13.21. Shionogi USA Inc
  • 13.22. Takeda Pharmaceutical Company Limited
  • 13.23. Vivus Inc
  • 13.24. VIVUS, Inc
  • 13.25. Zafgen Inc

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2026
  • FIGURE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, 2018-2026 (USD MILLION)
  • FIGURE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2020 VS 2026 (%)
  • FIGURE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2020 VS 2026 (USD MILLION)
  • FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2026
  • FIGURE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (%)
  • FIGURE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2026
  • FIGURE 31. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2026 (USD MILLION)
  • FIGURE 36. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 38. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 40. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. CALIFORNIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. FLORIDA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. ILLINOIS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. NEW YORK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. OHIO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. PENNSYLVANIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. TEXAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 53. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 54. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 55. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 56. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 64. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 65. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 66. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 76. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 77. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 78. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 79. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 80. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. CALIFORNIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. CALIFORNIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. CALIFORNIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. FLORIDA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. FLORIDA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. FLORIDA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. ILLINOIS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. ILLINOIS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. ILLINOIS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. NEW YORK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. NEW YORK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. NEW YORK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. OHIO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. OHIO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. OHIO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. PENNSYLVANIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. PENNSYLVANIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. PENNSYLVANIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. TEXAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. TEXAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. TEXAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: SCORES
  • TABLE 123. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: BUSINESS STRATEGY
  • TABLE 124. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: PRODUCT SATISFACTION
  • TABLE 125. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: RANKING
  • TABLE 126. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 127. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 128. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: MERGER & ACQUISITION
  • TABLE 129. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 130. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 131. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: INVESTMENT & FUNDING
  • TABLE 132. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 133. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: LICENSE & PRICING
  • TABLE 134. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: CONTACT DETAILS